complications of polyacrylamide gel filler in the asian in america

complications of polyacrylamide gel filler in the asian in america
Tags: , , , , , , , , ,
  • Why is polyacrylamide hydrogel banned in China?
  • Once a popular injectable filler, polyacrylamide hydrogel (PAAG) has been banned in China since 2006 due to its unclear safety and long-term complications. However, it is still being used worldwide because of its huge commercial profit, leading to emerging complications and an urgent need for standardized clinical management.
  • What is polyacrylamide hydrogel (Paag)?
  • 1. Introduction Polyacrylamide hydrogel (PAAG) is an extensively cross-linked polymeric hydrogel consisting of 2.5%–5% polyacrylamide and 95%–97.5% nonpyrogenic water.
  • What happens if a large amount of Paag is injected?
  • When a large amount of PAAG is injected, such as in breast augmentation, multiple deep injections with blind manipulation are usually required, which is likely to cause uneven injections and bleeding, leading to treatment-related complications. Table 2. The complication rate for different subgroups.
  • When did Paag become an injectable filler?
  • The clinical use of PAAG as an injectable filler started in Ukraine and has been extensively used for aesthetic purposes in European countries since the late 1980s.1,2 In December 1997, PAAG (“Interfall”, Ukraine Interfall Co., Ltd, Kyiv, Ukraine) entered China as an injectable filler.